Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Letter to the Editor

123I-MIBG Cardiac Scintigraphy and Heart/Mediastinum Ratio in Neurodegenerative Disorders: Is Delayed Scan Really Necessary?

Author(s): Susanna Nuvoli*, Barbara Palumbo, Andrea Marongiu, Francesco Bianconi and Angela Spanu

Volume 15, Issue 4, 2022

Published on: 01 August, 2022

Page: [257 - 258] Pages: 2

DOI: 10.2174/1874471015666220520090630

Price: $65

Next »
[1]
Frantellizzi, V.; Lavelli, V.; Ferrari, C.; Sardaro, A.; Farcomeni, A.; Pacilio, M.; Borrazzo, C.; Pani, R.; Rubini, G.; Vincentis, G. Diagnostic value of the early heart-to-mediastinum count ratio in cardiac 123i-mibg imaging for parkinson’s disease. Curr. Radiopharm., 2021, 14(1), 64-69.
[http://dx.doi.org/10.2174/1874471013999200727211633] [PMID: 32720610]
[2]
Maruyama, Y.; Yamada, T.; Murakami, K.; Kumano, R. Comparison of the diagnostic performance of H/M ratio between early and delayed phases for Lewy body disease. Nucl. Med. Commun., 2015, 36(5), 477-480.
[http://dx.doi.org/10.1097/MNM.0000000000000271] [PMID: 25714666]
[3]
Nuvoli, S.; Spanu, A.; Fravolini, M.L.; Bianconi, F.; Cascianelli, S.; Madeddu, G.; Palumbo, B. [123I]Metaiodobenzylguanidine (MIBG) cardiac scintigraphy and automated classification techniques in parkinsonian disorders. Mol. Imaging Biol., 2020, 22(3), 703-710.
[http://dx.doi.org/10.1007/s11307-019-01406-6] [PMID: 31309370]
[4]
Ricci, M.; Cimini, A.; Chiaravalloti, A.; Filippi, L.; Schillaci, O. Positron emission tomography (PET) and neuroimaging in the personalized approach to neurodegenerative causes of dementia. Int. J. Mol. Sci., 2020, 21(20), 7481.
[http://dx.doi.org/10.3390/ijms21207481] [PMID: 33050556]
[5]
Xu, D.; Zhu, W.; Huo, L.; Zhu, S.; Li, F.; Wang, H. Validation of Iodine-131-meta-iodobenzylguanidine cardiac scintigraphy in Parkinsonism: A preliminary study. Parkinsonism Relat. Disord., 2018, 50, 69-73.
[http://dx.doi.org/10.1016/j.parkreldis.2018.02.020] [PMID: 29475590]
[6]
Nuvoli, S.; Palumbo, B.; Malaspina, S.; Madeddu, G.; Spanu, A. 123I-ioflupane SPET and 123I-MIBG in the diagnosis of Parkinson’s disease and parkinsonian disorders and in the differential diagnosis between Alzheimer’s and Lewy’s bodies dementias. Hell. J. Nucl. Med., 2018, 21(1), 60-68.
[PMID: 29550847]
[7]
Agostini, D.; Verberne, H.J.; Hamon, M.; Jacobson, A.F.; Manrique, A. Cardiac 123I-MIBG scintigraphy in heart failure. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(4), 369-377.
[PMID: 19088691]
[8]
Teresińska, A. I-123-MIBG cardiac innervation imaging in patients with atrial fibrillation. J. Nucl. Cardiol., 2020, 27(6), 1951-1954.
[http://dx.doi.org/10.1007/s12350-019-01601-6] [PMID: 30694426]
[9]
Orimo, S.; Suzuki, M.; Inaba, A.; Mizusawa, H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: A systematic review and meta-analysis. Parkinsonism Relat. Disord., 2012, 18(5), 494-500.
[http://dx.doi.org/10.1016/j.parkreldis.2012.01.009] [PMID: 22321865]
[10]
Skowronek, C.; Zange, L.; Lipp, A. Cardiac 123I-MIBG scintigraphy in neurodegenerative parkinson syndromes: Performance and pitfalls in clinical practice. Front. Neurol., 2019, 10, 152.

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy